

Pharmaceuticals As a Key Element in Universal Health Coverage

For

7th Asia Pacific Future Trends Forum 2014 12-13 September 2014

Dr. Salmah bt. Bahri, RPh
Director of Pharmacy Practice & Development
Pharmaceutical Services Division
Ministry of Health Malaysia

OUTLINE

- Introduction
- Focus Areas for UHC
- Requirements for pharmaceuticals in UHC
- Challenges & strategies related to pharmaceuticals in UHC
- Way Forward
- Take Away Message

UNIVERSAL HEALTH COVERAGE (UHC)

- Access to good quality needed services
 - ✓ Prevention, promotion, treatment, rehabilitation and palliative care
- Financial protection
 - ✓ No one faces financial hardship or impoverishment by paying for needed services
- Equity
 - √ For everyone, universality

WHO Focus Area for UHC

- According to national priorities, give greater priority to surveillance, early detection, screening, diagnosis and treatment of non-communicable diseases and prevention and control, and to improving the accessibility to the safe, affordable, effective and quality medicines and technologies to diagnose and to treat them;
- Provide sustainable access to medicines and technologies, including through the development and use of evidence-based guidelines for the treatment of non-communicable diseases, and
- Efficient procurement and distribution of medicines in countries; and strengthen viable financing options and promote the use of affordable medicines, including generics, as well as improved access to preventive, curative, palliative and rehabilitative services, particularly at the community level

^{*}Based on OECD Health System Data 2012

What is Needed?



Emerging Needs

- Aging population
- Increase in chronic diseases & co-morbidities
- Higher expectations of citizens for quality service
- Increase demand of medicines as well as medical technology and services
- Increasing role of purchasing & paying institutions
- Higher focus on prevention

Main Principles for the UC Medical Benefit

➤ Drugs listed in the National Essential Medicines List (NEML)



Health Needs

Medicines are used in compliance to the NEML specified conditions or Clinical Practice Guideline (CPG)



Responsible Use

Why Access to Medicine is Important in UHC?


- Rising cost of healthcare delivery system is a major concern
- Drug expenditures are a major factor contributing to growth in health care expenditure. (Barnieh L, et al. 2014)
- Financing of pharmaceuticals in universal health coverage has been a major challenge
- Many new products will be presented to the market-increase expenditure
- Medicines strongly impact individuals and populations health; use scarce household resources

Pharmaceutical Expenditure

- Global medicines spending has surpassed US \$1 trillion per year
- Medicines spending accounts for up to 67% of total health expenditures in some countries, mostly paid out of pocket by consumers.
- Asian countries, pharmaceutical share of total health spending range between 8% -50%

Source :Wagner et al. BMC Health Services Research 2014 ; OECD/ WHO (2012), "Pharmaceutical expenditure" in Health at a Glance Asia Pacific 2012

Pharmaceutical expenditure as a share of total health expenditure, 2009 (Asia countries)



Source : OECD/WHO (2012), Pharmaceutical expenditure", in Health at a Glance: Asia pacific 2012

Major Challenges in UHC: Countries Sharing on Medicines Issues

- Battling with equity and ethical considerations for selection of medicines
- Sustainability issues on public-sector healthcare provision, drug price and Out-of-Pocket Money expenses
- How to ensure life-long treatment for chronic conditions, how to cover innovative, high-cost medicines?
- Fragmented decision-making across health, financing and other authorities, how to allocate limited resources?
- Addressing quality use of medicines, avoid wasting scarce resources
- Monitoring UHC

Issues on medicines need to be addressed, if not it will give impact to equity, access and sustainability of UHC

Approaches to Support Strategy Towards UHC for Pharmaceuticals



Regional Approaches to Support UHC Medicines Strategy

Building up knowledge networks:

➤ Technical assistance and networking in rational selection and use of medicines

- ➤ Medicines management and benefit policies
- > Sharing information for decision making
- > Financing drug benefits
- > Political and system challenges to covering medicines

National Medicines Policy Approach

Pharmaceutical Policy Objectives

Keeping Cost Affordable

To patients, society and to the health system



Encouraging Responsible Use

Necessary, safe, effective, properly taken and avoid wastage


Improving Equitable Access


Available to all especially the under privileged

National Medicines Policy

- Present a formal record values, aspirations, aims, decisions, actions medium to long-term government commitments
- Define national goals and objectives for pharmaceutical sector and set priorities
- Objectives: Accessibility, Quality and Rational Use of Medicines
- Identify strategies needed to meet set objectives, identify various player responsible for implementing
- Create forum for national discussions
- More than 100 countries have official NMP
- WHO's strategic directions for medicines 2008-2013:
 - One of new foci of NMP-Reimbursement as part of social security

Malaysian National Medicines Policy





Objectives of MNMP

To improve health outcomes of Malaysians through:

Promoting equitable access to essential medicines

Ensuring availability of safe, effective and affordable medicines of good quality

Promoting quality use of medicines by healthcare providers and consumers

5 Components of National Medicines Policy (Revised 2012)



Policy 3: Access To Medicines

An efficient and integrated medicines management and supply network shall be maintained.

The pharmaceutical industry shall be organised and regulated to create incentives and foster competition in medicine prices.

Appropriate financing mechanisms shall be developed to ensure essential medicines needed for quality healthcare are affordable

Policy 3: Access To Medicines

STRATEGIES

AVAILABILITY OF MEDICINES

Selection of Medicines

Supply of Medicines

ACCESS TO MEDICINES

AFFORDABILITY OF MEDICINES

National Pricing Reference for Medicines

Financing for Medicines

Generic Medicines Policy20

Affordability Of Medicines

STRATEGIES

National Pricing Reference for Medicines

- Transparency on Price information
- Monitoring of price information
- Tariffs and duties

Financing for Medicines

A reliable, affordable and sustainable financing mechanism shall be established

Generic Medicines Policy

Financing Drug Benefits Approach

Raising Funds

 Assess which options are available, potentially suitable, politically feasible and sustainable

Financing

Criteria used to evaluate financing mechanisms and selecting preferred method of finance

Resource Allocation

 Need to know how to prioritise between health system priorities, what formulas to use in allocating resources

Coverage decision

Decide on what, when, who and how to cover?

Procurement:

 Value assessment criteria, procurement prices and costs, regulations or distribution chain

Support functions:

 Regulatory system, quality assurance, performance monitoring and assessment, provider regulations

Way Forward

- Enhancing standards, systems and processes to support efficient and transparent decision making
- To make the best use of resources to maximize health benefits and to ensure the equity, efficiency and sustainability
- Strengthen policies and processes for selection, procuring and financing of effective quality assured medicines
- Focus on prevention strategy and monitoring of patients health outcome
- Enhancing knowledge sharing among countries

KEY TAKE AWAYS

Universal coverage means quality of health care for all delivered in ways that protect users from financial ruin or impoverishment. It is a powerful social equalizer, contributing to social cohesion and stability. **Not cheap...but when well planned, universal coverage is affordable**

The challenge is to expand health services with constant attention to causes of waste and inefficiency that can be reduced through smart policies and wise decisions

• WHO DG Dr. M. Chan , 2013

KEY TAKE AWAYS

- Achieving UHC without addressing medicines is not possible
- Decisions about medicines are political as well as technical
- Although contexts differ, medicines issues across countries are similar

THANK YOU



BETTER HEALTHCARE FOR BETTER FUTURE